Flags with the logos of the Danish drug maker Novo Nordisk, manufacturer of the blockbuster diabetes and weight loss treatments Ozempic and Wegovy are pictures, while the company introduces the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | AFP | Getty pictures
Novo Nordisk reported a better net profit in the first quarter on Wednesday, but lowered the forecast for the sales growth of the year as the imitator of the year, when imitators achieved the demand for the widespread loss medication with blockbuster weight loss.
The Danish pharmaceutical net profit reached 29.03 billion Danish crown ($ 4.4 billion) before the $ 27.8 billion of analysts in an LSEG survey.
Novo Nordisk's shares rose by 2.5%shortly after the market opened on Wednesday.
The sales of the company's popular changeable obesity medication annually increased by 83% at constant exchange rates to 17.36 billion Danish crown, somewhat below the 18.51 billion Danish crowns, which were expected by analysts in a factual set on Tuesday.
The total income at Novo Nordisk, which also produces diabetes and rare illness treatments, rose by 18% to 78.09 billion Danish crown compared to an expected 78.18 million Danish crown.
The sale of diabetes treatment in the first quarter was 32.72 billion Danish crown compared to forecasts of 31.5 billion Danish crown.
For 2025, the company now records sales growth of 13% to 21% in constant exchange rates, among the 16% to 24% previously predicted in February. Operating profit growth is forecast from 16% to 24%, compared to 19% to 27%.
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, attributed the reduced forecast to rising competition through increased weight loss medication in the USA
“In the first quarter of 2025 we achieved sales growth of 18% and further expanded the reach of our innovative GLP 1 treatments,” said Jørgensen in a statement.
“However, we have reduced our prospects for the overall year due to the GLP-1 penetration planned by Lerthan, which is influenced by the rapid expansion of the network in the USA.”
The US mediation pharmacies were allowed to make legal copies of Novos wide and diabetes -drug -s agents -Ozempics from the Food and Drug Administration (FDA) with a lack of drugs.
The FDA in February declared this deficiency about the mediation of pharmacies until May 22nd to hire the sale of copies of the drug. However, Jørgensen confirmed on Wednesday that the company would pursue companies that would continue to illegally distribute such imitators.
The competition heats up
The results come in the middle of the outstanding demand for the blockbuster GLP 1 weight loss treatments from the drug manufacturer, which imitate a hormone called glucagon-like peptide-1 to suppress the appetite.
However, the company had trouble shaking negative mood according to a number of disappointing test results for the obesity candidate of the next generation of Cagrisema.
Novo Nordisk confirmed on Wednesday that it should submit a regulatory approval of Cagrisema in the first quarter of 2026. In the meantime, she has applied for the regulatory approval of an oral version of her existing semaglutid treatment, which has the potential to “be the first oral GLP-1 treatment for obesity”.
The competition heats up on the market for weight loss medicines with pharmaceutical companies, including RochePresent Astrazeneca And Abbvie Everyone is currently developing potential new candidates.
The most important US competitor of Novos US competition, Eli Lilly, reported on Thursday about an expectation stay of 45% of sales in the first quarter, although the revenue for the popular weight loss drug-sept and lower drug prices were somewhat lower than expected. The US drug manufacturer also lowered his profit guidelines for the full year due to charges in connection with a shares recently used by cancer treatment contract.
Comments are closed.